Kevin Warsh's recent financial disclosure reveals a portfolio that combines sizable traditional investments with a scattering of early-stage, future-focused ventures. The document lists major positions that push total assets well above $100 million and also catalogs dozens of modest stakes grouped under DCM Investments 10 LLC, an entity with an aggregate market value reported at no more than $500,000.
Among the largest entries are two holdings in Juggernaut Fund LP, each exceeding $50 million. Those investments are linked in the filing to Warsh's advisory work for the Duquesne Family Office, the private investment firm associated with Stanley Druckenmiller.
Beyond those major positions, the filing contains a concentration of relatively small bets in companies that focus on advanced computing, decentralized finance, robotics and bioengineering. The mix reflects investments in firms that range from high-profile names to less well-known start-ups, and from speculative digital platforms to projects with active clinical development.
Well-known technology firms appear alongside niche ventures. SpaceX is listed among holdings familiar for satellite internet and ambitious space exploration plans. Polymarket, a prediction market platform, also appears on the disclosure. But the majority of the DCM Investments 10 LLC entries are modestly valued, suggesting early-stage exposure that could either fail or scale substantially.
The filing itemizes specific companies and brief descriptions of their activities, including:
- Recraft - described as an "AI vector art platform";
- Volt - an "AI physical security software" company;
- 11x - an "autonomous AI workforce platform";
- Outpace Bio - involved in protein engineering, a field noted in the filing for its potential when combined with AI;
- Partiful - a "social event planning platform";
- Cafe X - a "robotic coffee bar platform";
- Tenderly - an "ethereum developer platform";
- Stashfin - described as a "consumer lending neobank";
- Lemon Cash - a "crypto financial services platform".
The portfolio also includes investments tied to health and life sciences. The filing lists a company working on a herpes vaccine and another developing a reversible male contraceptive that is currently in clinical trials. There is mention of a "bionic" clothing company designed to assist movement, underscoring the diversity of biotech and medtech exposure within the roster.
In addition to hardware and therapeutics, the disclosure shows interest in digital humanization technologies. One holding identified as Delphi AI is described as a "digital cloning platform." The filing quotes the firm's website description:
"turn your knowledge into an interactive profile people can talk to. Showcase your expertise, answer repetitive questions, and discover what people want to know next,"
That description is presented in the filing as the company's own characterization of its service, a tool that could be used to create conversational profiles of expertise.
Overall, the portfolio juxtaposes established, high-value positions with a scattershot of sub-$500,000 stakes across companies pursuing cutting-edge applications of artificial intelligence, decentralized finance, robotics and biological engineering. The filing suggests Warsh's investment posture includes both large-scale, concentrated stakes and numerous smaller speculative positions that span several emerging sectors.
Embedded within the disclosure are implicit suggestions about the wide-ranging technological directions being pursued by private capital, from AI-driven creative tools and autonomous workforce systems to novel clinical programs and crypto infrastructure.
Separately, the filing illustrates the differing scales of exposure: the two Juggernaut Fund LP stakes exceeding $50 million each and the collective DCM Investments 10 LLC holdings capped at no more than $500,000 highlight a portfolio structured around major concentrated investments supplemented by many small, early-stage wagers.
What are the best investment opportunities in 2026? The filing itself does not answer that question but the range of assets it lists underscores how some investors allocate capital across both large, established positions and speculative bets on nascent technologies. The disclosure brings into focus the tension between concentrated portfolio anchors and a broad set of exploratory investments.